Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
LANSEN PHARMACEUTICAL HOLDINGS LIMITED |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 1.790 HKD | +40.94% | +2.87% | +21.95% | |
| Sep. 18 | Cathay International Pharma to Privatize Lansen Pharmaceutical in HK$239 Million Deal | MT |
| Aug. 25 | Lansen Pharmaceutical's H1 Profit Slides 17% | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Sales 2022 | 65.56 M 511 M | Sales 2023 * | - | Capitalization | 79.48 M 620 M |
|---|---|---|---|---|---|
| Net income 2022 | 8.00 M 62.36 M | Net income 2023 * | - | EV / Sales 2022 | 0,71x |
| Net cash position 2022 | 32.73 M 255 M | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 | 9,20x | P/E ratio 2023 * | Employees | 652 | |
| Yield 2022 | 3,30% | Yield 2023 * |
-
| Free-Float | 31.74% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +40.94% | ||
| 1 week | +3.47% | ||
| Current month | +4.68% | ||
| 1 month | +6.55% | ||
| 3 months | +20.13% | ||
| 6 months | +34.59% | ||
| Current year | +21.95% |
1 week
1.24
1.79
1 month
1.241.79
Current year
1.201.82
1 year
1.201.82
3 years
0.744.01
5 years
0.484.01
10 years
0.484.49
| Managers | Title | Age | Since |
|---|---|---|---|
Li Chen
CEO | Chief Executive Officer | 61 | 2018 |
Kai Fai Pang
SEC | Corporate Secretary | - | 2019 |
Yu Zhao
HRO | Human Resources Officer | 50 | 2015 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ching Har Chan
BRD | Director/Board Member | 66 | 2022 |
Zhen Tao Wu
CHM | Chairman | 69 | 2017 |
Kee Huen Chan
BRD | Director/Board Member | 71 | 2010 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-11-28 | 1.790 | +40.94% | 13,959,130 |
| 23-11-27 | 1.270 | -27.43% | 3,945,778 |
| 23-11-24 | 1.750 | -0.57% | 300,235 |
| 23-11-23 | 1.760 | 0.00% | 527,942 |
| 23-11-22 | 1.760 | +1.15% | 286,711 |
Delayed Quote Hong Kong Stock Exchange, November 28, 2023 at 03:08 am EST
More quotes
Lansen Pharmaceutical Holdings Limited is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The Company operates through three segments. Specialty Pharmaceuticals segment is engaged in the development, production and sales of specialty pharmaceuticals mainly used in the fields of rheumatology and dermatology. Its main specialty pharmaceutical products include pafulin, leflunomide tablets and mycophenolate mofetil dispersible tablets. Plant Extract and Healthcare Products segment is engaged in the development, production and sales of Chinese medicine extracts and healthcare products. Other Pharmaceuticals segment is engaged in businesses related to other pharmaceuticals.
Sector
Pharmaceuticals
Calendar
2024-03-25
- Q4 2023 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +21.95% | 68 M $ | |
| +61.71% | 532 B $ | |
| +46.67% | 464 B $ | |
| -14.16% | 364 B $ | |
| -14.56% | 246 B $ | |
| -18.80% | 216 B $ | |
| +2.02% | 201 B $ | |
| -11.75% | 195 B $ | |
| -42.06% | 170 B $ | |
| +1.10% | 141 B $ |
